Cynata Therapeutics Company Description
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease.
It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation.
Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products.
The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013.
Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
| Country | Australia |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Kilian Kelly |
Contact Details
Address: 100 Cubitt Street Cremorne, 3121 Australia | |
| Phone | 61 3 7067 6940 |
| Website | cynata.com |
Stock Details
| Ticker Symbol | CYYNF |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000CYP7 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kilian Kelly | MD, Chief Executive Officer and Director |
| Dr. Jolanta Airey | Chief Medical Officer |
| Dr. Mathias Kroll | Chief Business Officer |
| Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |